It has also been reported that the administration of anti-CTLA-4 in patients with metastatic melanoma has shown a durable tumor immune response in phase I and phase II clinical studies through CD28–B7-mediated Treg cell activation against TAA [113,114]. This evidence concerns the gene CD80 and neoplasm.